Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's sales prospects. The US regulator has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results